最新公告列表 《2025年度业绩快报公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年2月27日收盘，春立医疗（688236）报收于22.38元，较前一交易日上涨0.72%，最新总市值 为85.84亿元。该股当日开盘22.2元，最高22.54元，最低22.15元，成交额达3596.92万元，换手率为 0.56%。 近日，北京市春立正达医疗器械股份有限公司发布2025年度业绩快报，营业总收入为1,043,768,680.27 元，同比增长29.52%；归属于母公司所有者的净利润为272,124,670.05元，同比增长117.72%。报告期末 总资产为3,659,165,538.06元，较期初增长5.58%；归属于母公司的所有者权益为2,985,050,158.61元，较 期初增长5.86%。业绩增长主要得益于产品集采落地后销量提升、国际化业务拓展以及运营效率优化。 ...

Core Viewpoint - The company reported a total operating revenue of 1.783 billion yuan for the year 2025, reflecting an 18.79% increase compared to the previous year, while the net profit attributable to shareholders decreased by 2.79% to 155 million yuan [1] Group 1: Financial Performance - The total operating revenue reached 1.783 billion yuan, marking an 18.79% year-on-year growth [1] - The net profit attributable to the parent company's shareholders was 155 million yuan, a decrease of 2.79% from the previous year [1] - The net profit after deducting non-recurring gains and losses was 125 million yuan, down 6.80% year-on-year [1] Group 2: Operational Highlights - The company successfully implemented its convertible bond fundraising projects, leading to a gradual release of new production capacity [1] - There was a continuous increase in customer orders, contributing to a steady rise in shipment volumes [1] - The stable gross profit margin and revenue growth directly supported the increase in gross profit, providing core support for performance growth [1]

Group 1 - The core point of the article is that Jinghua Microelectronics Co., Ltd. reported a significant increase in revenue for the fiscal year 2025, but also a substantial net loss attributed to various factors including goodwill impairment and increased R&D expenses [1] - As of February 27, 2026, Jinghua Micro's stock closed at 24.61 yuan, down 1.36% from the previous trading day, with a total market capitalization of 2.975 billion yuan [1] - The company's total revenue for 2025 was 173.58 million yuan, representing a year-on-year growth of 28.73% [1] - The net profit attributable to the parent company was a loss of 42.69 million yuan, which reflects a year-on-year increase in losses of 315.63% [1] - The decline in total assets was noted at 130.48 million yuan, a decrease of 8.62% compared to the beginning of the period [1] - The company's share capital increased by 30.03% due to capital reserve conversion and the vesting of restricted stock under equity incentives [1] - The company is currently under investigation by the China Securities Regulatory Commission, with no conclusive opinions received yet [1]

Core Viewpoint - Kangpeng Technology (688602.SH) reported a revenue of 772 million yuan for the fiscal year 2025, marking a year-on-year increase of 14.34%, but also recorded a net loss attributable to shareholders of 60.55 million yuan [1] Group 1: Financial Performance - The company achieved an operating income of 772 million yuan, which is a 14.34% increase compared to the previous year [1] - The net loss attributable to the parent company's shareholders was 60.55 million yuan [1] - The net loss attributable to the parent company, excluding non-recurring gains and losses, was 78.92 million yuan [1] Group 2: Business Operations - The company steadily advanced its product sales during the reporting period [1] - The growth in the CDMO (Contract Development and Manufacturing Organization) segment positively impacted the company's revenue [1] - The overall gross profit margin slightly increased, and cost control measures led to a reduction in period expenses compared to the previous year [1]

Core Viewpoint - Ruiang Gene (688217.SH) reported a significant decline in revenue and incurred net losses for the fiscal year 2025, primarily due to intensified competition in the in vitro diagnostics industry and specific events affecting the company [1] Financial Performance - The company achieved total operating revenue of 174 million yuan, representing a year-on-year decrease of 28.19% [1] - The net loss attributable to shareholders of the parent company was 49.8836 million yuan [1] - The net loss attributable to shareholders of the parent company, after deducting non-recurring gains and losses, was 58.2004 million yuan [1] - Basic loss per share was 0.9 yuan [1] Industry Context - The decline in revenue is attributed to increased competition within the in vitro diagnostics sector [1] - The company faced challenges due to specific events that impacted its operational performance [1]

Group 1 - The core point of the article highlights that 科润智控 (KORUN Intelligent Control) reported a decline in net profit for the year 2025, despite a slight increase in revenue [1] - The company's revenue for 2025 reached approximately 1.43 billion yuan, representing a year-on-year growth of 5.86% [1] - The net profit attributable to shareholders was approximately 15.91 million yuan, showing a significant year-on-year decrease of 62.87% [1] - The net profit after deducting non-recurring gains and losses was about 3.12 million yuan, reflecting a drastic decline of 91.81% year-on-year [1] - The decline in profit is attributed to intensified industry competition, rising raw material costs, increased operating expenses, and higher financial costs [1] Group 2 - As of February 27, 2026, the stock price of 科润智控 closed at 12.31 yuan, down 2.15% from the previous trading day, with a total market capitalization of 2.32 billion yuan [1] - The total assets of the company amounted to approximately 2.03 billion yuan, marking a growth of 3.73% compared to the beginning of the period [1] - The owner's equity increased by 4.19% to approximately 745.76 million yuan [1]

华恒生物(688639.SH)发布2025年度业绩快报，2025年度，公司预计实现营业收入28.86亿元，同比增加 32.50%;预计实现归属于母公司所有者的净利润1.31亿元，同比减少30.97%。 报告期内，氨基酸、维生素行业面临阶段性供需失衡，行业市场竞争激烈，公司主要产品缬氨酸、肌醇 年平均价格较去年同期下降，且公司新项目效益尚未体现，对公司利润产生影响，同时，伴随公司经营 规模扩大，公司各项费用较去年同期增加，公司整体利润较去年同期减少。 ...

报告期内，氨基酸、维生素行业面临阶段性供需失衡，行业市场竞争激烈，公司主要产品缬氨酸、肌醇 年平均价格较去年同期下降，且公司新项目效益尚未体现，对公司利润产生影响，同时，伴随公司经营 规模扩大，公司各项费用较去年同期增加，公司整体利润较去年同期减少。 智通财经APP讯，华恒生物(688639.SH)发布2025年度业绩快报，2025年度，公司预计实现营业收入 28.86亿元，同比增加32.50%;预计实现归属于母公司所有者的净利润1.31亿元，同比减少30.97%。 ...

（文章来源：证券日报） 证券日报网讯 2月27日，太阳纸业发布公告称，公司2025年度实现营业总收入39184218359.14元，同比 下降3.79%；归属于上市公司股东的净利润为3257857931.51元，同比增长5.05%。 ...

北京商报讯（记者 陶凤 王天逸）2月27日，上纬新材发布2025年度业绩快报。公告显示，公司2025年实 现营业总收入17.97亿元，同比增长20.27%；但归属于母公司所有者的净利润为4095万元，同比大幅下 滑53.82%，扣除非经常性损益后的净利润为3253万元，同比降幅达59.51%。 对于业绩变动，公司表示，主要系报告期内为提升产品核心竞争力、探索业务新方向，加大了新材料业 务研发投入，导致利润端承压。 ...